Investigation Launched by M&A Class Action Firm on SpringWorks Therapeutics Merger with Merck KGaA Monteverde & Associates PC is investigating the proposed merger between SpringWorks Therapeutics and Merck KGaA. Shareholders may receive $47.00 per share.

Investigation Launched by M&A Class Action Firm on SpringWorks Therapeutics Merger with Merck KGaA #United_States #New_York #Monteverde_Associates #Merck_KGaA #SpringWorks_Therapeutics

Rappta Therapeutics and SpringWorks Forge a License Agreement for RPT04402 Targeting Uterine Cancer Treatments Rappta Therapeutics has formed an exclusive global licensing agreement with SpringWorks for the development of RPT04402, targeting PP2A for uterine cancers.

Rappta Therapeutics and SpringWorks Forge a License Agreement for RPT04402 Targeting Uterine Cancer Treatments #Finland #Helsinki #Rappta_Therapeutics #RPT04402 #SpringWorks_Therapeutics